Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously... see more

Recent & Breaking News (NDAQ:IOVA)

Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates

GlobeNewswire August 4, 2022

Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022

GlobeNewswire July 27, 2022

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire July 22, 2022

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 17, 2022

Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

GlobeNewswire June 13, 2022

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire June 8, 2022

Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

GlobeNewswire May 26, 2022

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire May 20, 2022

Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates

GlobeNewswire May 5, 2022

Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting

GlobeNewswire April 27, 2022

Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022

GlobeNewswire April 26, 2022

Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

GlobeNewswire April 25, 2022

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire April 22, 2022

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire April 12, 2022

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

GlobeNewswire April 5, 2022

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire March 16, 2022

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire March 15, 2022

Iovance Biotherapeutics' Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)

GlobeNewswire March 15, 2022

Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

GlobeNewswire March 8, 2022

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates

GlobeNewswire February 24, 2022